Will Zura Bio announce topline results from the TibuSHIELD trial of tibulizumab in hidradenitis suppurativa by December 31, 2026?
deadline 2026-12-31
confidence medium
tier 4 evidence
60%Asturna estimate
Resolution criterion
Yes if, no later than December 31, 2026, Zura Bio publicly reports the topline results of the TibuSHIELD trial of tibulizumab (the outcome on the primary endpoint, positive or negative) in a press release or SEC filing. The deadline is the last day of the period the company gave in its filing ("fourth quarter of 2026"). An announcement of a delay or of a new timeline, enrollment or interim data that do not report the primary-endpoint outcome, or the absence of any announcement by that date, resolves NO.
Verified starting state
As of October 28, 2026: according to the Zura Bio filing of October 27, 2026, the company expects topline results in the period "fourth quarter of 2026". Source: https://www.sec.gov/Archives/edgar/data/1855644/000185564426000012/zura-20261027xex991.htm
What pushes it up
- Zura Bio’s Oct 27 2026 SEC filing states the company expects topline results in Q4 2026 (tier 1)
- The company reported exceeding enrollment targets for the trial (tier 4)
What pushes it down
- The filing is a forward‑looking statement, not a guarantee (tier 1)
- Only a tier 4 press article supports progress; no tier 1/2 confirmation of data collection or analysis
- Biotech trials often experience delays, reducing the likelihood of meeting the exact deadline
What would move this number most
Whether the trial data collection and analysis will be completed in time for a Q4 2026 topline release
How this number is built
| Deadline | 2026-12-31 |
| Base rate | 60% |
| Best evidence | tier 4 · 1 article(s) used |
| Independent runs | 55 · 65 (spread 10 pts) |
| Confidence | medium |
| Evidence cap | not triggered |
| Last revised | 2026-10-28 15:08 |
| Model | openai/gpt-oss-120b (Groq) |
Sources consulted